PureTech Competitors
| PRTC Stock | USD 18.80 0.11 0.59% |
PureTech Health vs Neumora Therapeutics Correlation
Good diversification
The correlation between PureTech Health PLC and NMRA is -0.15 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding PureTech Health PLC and NMRA in the same portfolio, assuming nothing else is changed.
Moving against PureTech Stock
| 0.83 | KURA | Kura Oncology | PairCorr |
| 0.82 | ABP | Abpro Holdings | PairCorr |
| 0.71 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.48 | GNLX | Genelux Common | PairCorr |
| 0.48 | LYRA | Lyra Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PureTech Health's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PureTech Health Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between PureTech Health and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of PureTech and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of PureTech Health PLC does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between PureTech Stock performing well and PureTech Health Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze PureTech Health's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AUTL | 3.82 | (0.12) | 0.00 | 0.00 | 0.00 | 10.45 | 30.76 | |||
| NGNE | 3.84 | (1.00) | 0.00 | (0.38) | 0.00 | 6.59 | 23.85 | |||
| SLDB | 3.57 | 0.34 | 0.08 | 0.25 | 4.18 | 11.36 | 21.63 | |||
| QSI | 3.36 | (1.09) | 0.00 | (0.34) | 0.00 | 6.50 | 15.95 | |||
| LCTX | 3.06 | (0.08) | 0.00 | (0.02) | 0.00 | 4.65 | 13.49 | |||
| BNTC | 3.14 | (0.36) | 0.00 | (0.22) | 0.00 | 5.86 | 25.13 | |||
| ADCT | 3.33 | (0.16) | 0.00 | (0.07) | 0.00 | 8.49 | 22.84 | |||
| ALMS | 6.00 | 3.11 | 0.73 | 1.41 | 2.85 | 10.41 | 103.99 | |||
| RCKT | 2.87 | (0.17) | 0.00 | (0.08) | 0.00 | 8.04 | 16.20 | |||
| NMRA | 3.56 | (0.49) | 0.00 | (0.49) | 0.00 | 8.04 | 33.25 |
Cross Equities Net Income Analysis
Compare PureTech Health PLC and related stocks such as Autolus Therapeutics, Neurogene, and Solid Biosciences LLC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUTL | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (7.5 M) | (12.6 M) | (19.7 M) | (31.1 M) | (123.8 M) | (142.1 M) | (142.1 M) | (148.8 M) | (208.4 M) | (220.7 M) | (198.6 M) | (188.7 M) |
| NGNE | (10.5 M) | (10.5 M) | (7.7 M) | (8.7 M) | (23.8 M) | (21.9 M) | (37 M) | (50.2 M) | (31.6 M) | (69.4 M) | (33.3 M) | (50.5 M) | (55.2 M) | (36.3 M) | (75.1 M) | (67.6 M) | (64.2 M) |
| SLDB | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (21.5 M) | (52.1 M) | (74.8 M) | (117.2 M) | (88.3 M) | (72.2 M) | (86 M) | (96 M) | (124.7 M) | (112.2 M) | (117.8 M) |
| QSI | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (36.6 M) | (95 M) | (132.4 M) | (96 M) | (101 M) | (90.9 M) | (95.5 M) |
| LCTX | (700 K) | (16.5 M) | (21.4 M) | (43.9 M) | (36.4 M) | (47 M) | 33.6 M | (20 M) | (46 M) | (11.7 M) | (20.6 M) | (43 M) | (26.3 M) | (21.5 M) | (18.6 M) | (16.7 M) | (17.6 M) |
| BNTC | (6.4 M) | (6.4 M) | (6.4 M) | (10.8 M) | (8.8 M) | (18.5 M) | (4.4 M) | (8.6 M) | 2.9 M | (8.3 M) | (13.9 M) | (18.2 M) | (19.6 M) | (21.8 M) | (37.9 M) | (34.1 M) | (32.4 M) |
| ADCT | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (123.1 M) | (116.5 M) | (246.3 M) | (230 M) | (157.1 M) | (240.1 M) | (157.8 M) | (142.1 M) | (149.2 M) |
| ALMS | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (155 M) | (294.2 M) | (264.8 M) | (278.1 M) |
| RCKT | (6.1 M) | (6.1 M) | (6.1 M) | (7.6 M) | (9.5 M) | (68 M) | (42.9 M) | (29.5 M) | (74.5 M) | (83.2 M) | (146.7 M) | (169.1 M) | (221.9 M) | (245.6 M) | (258.7 M) | (232.9 M) | (221.2 M) |
| NMRA | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (237.3 M) | (130.9 M) | (235.9 M) | (243.8 M) | (219.4 M) | (230.4 M) |
PureTech Health PLC and related stocks such as Autolus Therapeutics, Neurogene, and Solid Biosciences LLC Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in PureTech Health PLC financial statement analysis. It represents the amount of money remaining after all of PureTech Health PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.PureTech Health Competitive Analysis
The better you understand PureTech Health competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, PureTech Health's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across PureTech Health's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
PureTech Health Competition Performance Charts
Five steps to successful analysis of PureTech Health Competition
PureTech Health's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by PureTech Health PLC in relation to its competition. PureTech Health's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of PureTech Health in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact PureTech Health's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to PureTech Health PLC, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your PureTech Health position
In addition to having PureTech Health in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Check out PureTech Health Correlation with its peers. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Biotechnology sector continue expanding? Could PureTech diversify its offerings? Factors like these will boost the valuation of PureTech Health. Anticipated expansion of PureTech directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PureTech Health data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.615 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 5.427 | Return On Assets |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PureTech Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PureTech Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PureTech Health's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.